Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Should l Buy ?
Source: Newsfilter
Oncocyte's Participation in Conference: Oncocyte Corp. will be represented by CEO Josh Riggs and CFO Andrea James at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025, where they will discuss the company's innovative diagnostic technologies and progress on a regulated organ transplant rejection monitoring test kit.
Company Overview and Products: Oncocyte specializes in diagnostics technology, offering tests like VitaGraft™ for organ transplantation monitoring and DetermaIO™ for assessing tumor responses to immunotherapies, aiming to enhance clarity and confidence for physicians and patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
